

SUBMISSION DATE:

Enter sequence variants from your cohort into the table below. Please begin each variant on a new line. For compound heterozygous variants, enter a linking ID in the first column. You need only enter details unique to the second variant.

Gene

##Local ID / Linking ID	Gene symbol	Genome build	Reference sequence	HGVS
Local ID Optional, but highly recommended. The stable unique identifier your organisation uses to identify this variant. Linking ID REQUIRED if submitting compound heterozygous variants.	Required. This must be the preferred symbol from HGNC. (https://www.genenames.org/)	Required. The genome assembly that was used to call variants in this submission. All variants in this file should use the same genome assembly. Allowed values: NCBI36, hg18, GRCh37, hg19, GRCh38, hg38.	Required. The reference sequence for the HGVS expression provided in the next column, e.g. NM_000492.3, NG_016465.3, or NC_000007.13.	Required. Provide the c. or g. portion of the nucleotide HGVS expression for the variant(s) being reported related to condition.

Please start your submission in the next row. For compound heterozygous variants, enter the details of the second variant in a new row and provide a linking ID.

Variant definition

Chromosome	Start	Stop	Reference allele	Alternate allele	Molecular consequence
Required. Provide the chromosome number.	Required. The start location for the reference allele in chromosome coordinates.	Required. The stop location for the reference allele in chromosome coordinates.	Required. The reference allele for the submitted variant. For an insertion, enter '${}_{-}$'. For a deletion, enter '${}_{+}$'.	Required. The alternate allele for the submitted variant. For a deletion, enter '${}_{-}$'.	Required. The predicted effect of a variant on a biological sequence as described by Sequence Ontology. Select all that apply.

Interpreted condition - the condition for which you are interpreting the variant

Clinical significance

Condition ID type	Condition name	Condition comment	Variant classification	Date last evaluated	Assertion method
Required. Please specify the reference database for the condition name. Allowed values are: OMIM, HPO, MONDO.	Required. Please specify the condition name/ID curated against. Standard ontology term required.	Optional. Free text describing the condition observed in individuals with this variant.	Required. Click cell for drop-down list; allowed values include Pathogenic, Likely pathogenic, Uncertain significance, Likely benign, Benign, Cannot be classified.	Optional. Date the clinical significance of the variant was last evaluated by the submitter. If not available, leave blank. Please use the format yyyy-mm-dd.	Strongly recommended. The method used to for interpretation. (e.g. ACMG guidelines)

Details of test and individuals tested

ACMG evidence criteria (e.g. BA1)	Interpretation summary	Mode of inheritance	Allele origin	Zygosity	Affected status
Required. Provide the ACMG evidence criteria applied. Select all that apply.	Required. Provide a summary of the variant interpretation.	Required. Supported values are from the Human Phenotype Ontology (HPO). Allowed values include: Autosomal dominant inheritance, Autosomal recessive inheritance, Autosomal unknown, Codominant, Genetic anticipation, Mitochondrial inheritance, Oligogenic, Sex-limited autosomal dominant, Somatic mutation, Sporadic, X-linked inheritance, Y-linked inheritance, Other. If you provide Other, please specify, e.g. Other:new mode of inheritance.	Required. The genetic origin of the variant for individuals in each aggregate observation. Allowed values: germline, de novo, somatic, maternal, paternal, inherited, unknown, uniparental, biparental. Note that biparental and uniparental are intended for the context of uniparental disomy. If you'd like to indicate zygosity, please report counts of homozygotes and heterozygotes in columns BV-BY. For <i>de novo</i> variants, please indicate " <i>de novo</i> ", not the origin of the chromosome.	Required. Indicate zygosity for the variant in the individual. Allowed values: Single heterozygote, compound heterozygote, homozygote, hemizygote.	Required: Indicate whether or not the individuals in each aggregate observation had the interpreted condition. Allowed values: yes, no, unknown.

Details of testing results

Clinical features	Comment on clinical features	Tissue	Other family members tested	Family ID	Segregation observed
Required. Provide a list of clinical features observed in these individuals. HPO terms may be used to indicate the clinical features. Separate multiple terms with a semicolon. If you wish to provide a free text comment on the observed phenotype, please use the "Comment on clinical features" column.	Optional. To provide a free text explanation of clinical features provided in the previous column, e.g. to describe the progression of disease or diagnosis.	Optional. Tissue sampled to assay the variation. Highly recommended for somatic variants.	Required. List other family members tested. If no family members have been tested enter '-'	Strongly recommended. If you would like to indicate which cases (represented on different rows) were part of the same family, please provide an anonymous identifier for the family.	Required. Indicate whether segregation of the variant and reported condition was observed in this individual's family.

	Population data				Methods.
Number of individuals with variant	Number of homozygotes	Number of single heterozygotes	Number of compound heterozygotes	Number of hemizygotes	Test name or type
Required. The total number of individuals with the variant allele.	Strongly recommended. Number of individuals homozygous for the variant.	Optional. Number of individuals who are single heterozygotes for the variant.	Optional. Number of individuals who are compound heterozygotes, where another pathogenic variant was identified.	Optional. Number of individuals who are hemizygous for the variant.	Strongly recommended. The name or type of test used to identify this variant. If the test is registered with the Genetic Test Registry (GTR), please submit the GTR Test ID, e.g. GTR000074114.1.

			General Comments
Platform type	Platform name	Testing laboratory	Comment
Strongly recommended. Type of platform used for data capture, e.g. next-gen sequencing, microarray.	Optional. Name of platform used for data capture, e.g. HiSeq, MiSeq.	Required. Please indicate the name of the testing lab.	Optional. Free text. You can put important information that isn't included in any of the other fields here.